Last reviewed · How we verify
Paclitaxel injection intravenous infusion
Paclitaxel injection intravenous infusion is a Taxane; microtubule stabilizer Small molecule drug developed by LaNova Medicines Limited. It is currently in Phase 3 development for Metastatic carcinoma of the ovary, Breast cancer (metastatic and adjuvant), Non-small cell lung cancer.
Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.
Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells. Used for Metastatic carcinoma of the ovary, Breast cancer (metastatic and adjuvant), Non-small cell lung cancer.
At a glance
| Generic name | Paclitaxel injection intravenous infusion |
|---|---|
| Sponsor | LaNova Medicines Limited |
| Drug class | Taxane; microtubule stabilizer |
| Target | β-tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel is a taxane that binds to the β-subunit of tubulin dimers and stabilizes microtubule polymers, preventing their normal dynamic instability. This leads to disruption of mitotic spindle formation, cell cycle arrest in the G2/M phase, and ultimately triggers apoptosis in rapidly dividing cancer cells. It is effective against a broad range of solid tumors.
Approved indications
- Metastatic carcinoma of the ovary
- Breast cancer (metastatic and adjuvant)
- Non-small cell lung cancer
- Kaposi's sarcoma
- Gastric adenocarcinoma
Common side effects
- Neutropenia
- Peripheral neuropathy
- Myalgia/arthralgia
- Alopecia
- Nausea/vomiting
- Diarrhea
- Hypersensitivity reactions
- Mucositis
Key clinical trials
- A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (PHASE2)
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (PHASE3)
- Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer (PHASE2)
- A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paclitaxel injection intravenous infusion CI brief — competitive landscape report
- Paclitaxel injection intravenous infusion updates RSS · CI watch RSS
- LaNova Medicines Limited portfolio CI
Frequently asked questions about Paclitaxel injection intravenous infusion
What is Paclitaxel injection intravenous infusion?
How does Paclitaxel injection intravenous infusion work?
What is Paclitaxel injection intravenous infusion used for?
Who makes Paclitaxel injection intravenous infusion?
What drug class is Paclitaxel injection intravenous infusion in?
What development phase is Paclitaxel injection intravenous infusion in?
What are the side effects of Paclitaxel injection intravenous infusion?
What does Paclitaxel injection intravenous infusion target?
Related
- Drug class: All Taxane; microtubule stabilizer drugs
- Target: All drugs targeting β-tubulin
- Manufacturer: LaNova Medicines Limited — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic carcinoma of the ovary
- Indication: Drugs for Breast cancer (metastatic and adjuvant)
- Indication: Drugs for Non-small cell lung cancer